Literature DB >> 12713992

Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy.

Mark Robson1, Martee Hensley, Richard Barakat, Carol Brown, Dennis Chi, Elizabeth Poynor, Kenneth Offit.   

Abstract

OBJECTIVES: Women at risk for ovarian cancer may consider risk-reducing salpingo-oophorectomy (RRSO), and desire information regarding the health consequences of the procedure. We studied women who had undergone RRSO to assess quality of life after the procedure.
METHODS: Women (n = 59) undergoing RRSO between 1 January 1997 and 31 July 2000 completed a questionnaire composed of the Symptom Checklist (SCL), the Medical Outcomes Study SF-36 Health Survey, the Center for Epidemiological Studies Depression Scale, the Impact of Events Scale, and the Sexual Functioning Questionnaire-Female.
RESULTS: At a mean of 23.8 months after RRSO, overall quality of life was similar to that reported for the general population and for breast cancer survivors. Estrogen deprivation symptoms, particularly vaginal dryness (35.2%) and dyspareunia (27.7%), were commonly bothersome. Genital symptoms resulting in sexual dysfunction were the most significant predictors of satisfaction with surgery. The prevalence of depression (20.4%) was similar to that of the general population, but a significant proportion of the group (20.7%) continued to report significant ovarian cancer-specific worries despite surgery.
CONCLUSION: Vaginal symptoms are bothersome to women who have undergone RRSO, but overall health and psychological outcomes are not impaired. Although coital symptoms may not be a direct consequence of RRSO, they are the most important predictors of satisfaction. A proportion of women continue to report worries about ovarian cancer after surgery, and these women are at risk for psychological distress.

Entities:  

Mesh:

Year:  2003        PMID: 12713992     DOI: 10.1016/s0090-8258(03)00072-6

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  34 in total

1.  What is the clinically relevant endpoint for cancer prevention trials?

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

2.  A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors.

Authors:  Jeanne Carter; Shari Goldfarb; Raymond E Baser; Deborah J Goldfrank; Barbara Seidel; Lisania Milli; Sally Saban; Cara Stabile; Jocelyn Canty; Ginger J Gardner; Elizabeth L Jewell; Yukio Sonoda; Marisa A Kollmeier; Kaled M Alektiar
Journal:  Gynecol Oncol       Date:  2020-06-08       Impact factor: 5.482

Review 3.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

Review 4.  Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.

Authors:  Roi Tschernichovsky; Annekathryn Goodman
Journal:  Oncologist       Date:  2017-03-17

5.  Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.

Authors:  Sharon L Bober; Christopher J Recklitis; Jennifer Bakan; Judy E Garber; Andrea F Patenaude
Journal:  J Sex Med       Date:  2014-10-14       Impact factor: 3.802

Review 6.  Salpingectomy as a means to reduce ovarian cancer risk.

Authors:  Mary B Daly; Charles W Dresher; Melinda S Yates; Joanne M Jeter; Beth Y Karlan; David S Alberts; Karen H Lu
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-13

7.  Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer.

Authors:  Cyril Touboul; Catherine Uzan; Jean Laurent Ichanté; Olivier Caron; Ariane Dunant; Sarah Dauchy; Sébastien Gouy; Brigitte Bressac de Paillerets; Philippe Morice; Suzette Delaloge
Journal:  Oncologist       Date:  2011-07-17

8.  Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Authors:  Allison W Kurian; Bronislava M Sigal; Sylvia K Plevritis
Journal:  J Clin Oncol       Date:  2009-12-07       Impact factor: 44.544

9.  A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.

Authors:  Carolyn Y Fang; Carol Cherry; Karthik Devarajan; Tianyu Li; John Malick; Mary B Daly
Journal:  Gynecol Oncol       Date:  2009-01-13       Impact factor: 5.482

10.  A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.

Authors:  Mark H Greene; Marion Piedmonte; Dave Alberts; Mitchell Gail; Martee Hensley; Zoe Miner; Phuong L Mai; Jennifer Loud; Gustavo Rodriguez; Jack Basil; John Boggess; Peter E Schwartz; Joseph L Kelley; Katie E Wakeley; Lori Minasian; Stephen Skates
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.